Clinical research

DOI: 10.4244/EIJ-D-23-00011

Transcatheter aortic valve implantation in patients with extra-small aortic annuli

Gabriela Tirado-Conte1, MD; Josep Rodés-Cabau2, MD, PhD; Juan F. Oteo3, MD; Manuel Pan4, MD, PhD; Erika Muñoz5, MD; Guy Witberg6, MD; Asim N. Cheema7,8, MD; Alberto Alperi2, MD; Diego Lopez9, MD; Ignacio J. Amat-Santos10, MD, PhD; Mariama Akodad11, MD, PhD; Soledad Ojeda4, MD; Vicenc Serra12, MD; Sergio Garcia-Blas13, MD; Fernando Alfonso14, MD, PhD; Ole De Backer15, MD, PhD; Luis Asmarats16, MD, PhD; Antonio Muñoz5, MD; Ashraf Hamdan6, MD; Stefan Toggweiler17, MD; Raquel del Valle18, MD; Luisa Salido19, MD, PhD; Ignacio Cruz-González20, MD, PhD; Rodrigo Estevez-Loureiro21, MD, PhD; Luis Enrique Martin Alfaro22, MD; Livia Gheorghe22, MD; Maciec Dabrowski23, MD; Alberto Berenguer24, MD; Dabit Arzamendi14, MD, PhD; Francesco Saia25, MD; John G. Webb10, MD; Lars Sondergaard26, MD, PhD; Luis Nombela-Franco1, MD, PhD

Abstract

Background: A small aortic annulus (SAA) is a risk factor for prosthesis-patient mismatch (PPM) in patients undergoing surgical or transcatheter aortic valve implantation (TAVI). Data regarding TAVI in patients with extra-SAA are scarce.

Aims: The aim of this study was to analyse the safety and efficacy of TAVI in patients with extra-SAA.

Methods: A multicentre registry study including patients with extra-SAA (defined as an aortic annulus area <280 mm2 and/or perimeter <60 mm) undergoing TAVI was established. Primary efficacy and safety endpoints were defined as device success and early safety at 30 days, respectively, using the Valve Academic Research Consortium-3 criteria, and were analysed according to valve type: self-expanding (SEV) versus balloon-expandable (BEV).

Results: A total of 150 patients were included, of which 139 (92.7%) were women, and 110 (73.3%) received an SEV. Intraprocedural technical success was 91.3%, with a higher rate in patients receiving an SEV (96.4% vs 77.5% with BEV; p=0.001). Overall, 30-day device success was 81.3%, (85.5% with SEV vs 70.0% with BEV; p=0.032). The primary safety endpoint occurred in 72.0% of patients (with no...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 19 Number 4
Jul 17, 2023
Volume 19 Number 4
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00028 Jun 19, 2023
The ongoing quest for optimal transcatheter aortic valve implantation for patients with small annuli
Hayashida K and Kobari Y
free

Clinical research

10.4244/EIJ-D-19-00236 Jun 12, 2019
Annular versus supra-annular sizing for TAVI in bicuspid aortic valve stenosis
Kim W et al
free

SHORT REPORT

10.4244/EIJ-D-18-00137 Jun 14, 2018
First experience with the 34 mm self-expanding Evolut R in a multicentre registry
Harnath A et al
free

Editorial

10.4244/EIJ-E-23-00039 Sep 18, 2023
Transcatheter aortic valve implantation: the shape matters
Kim W and Holzamer A
free

Editorial

10.4244/EIJ-E-22-00034 Oct 21, 2022
Is transcatheter aortic valve implantation safe in patients with left ventricular outflow tract calcification?
Søndergaard L and Mylotte D
free
Trending articles
188.3

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
170.15

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
159.45

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
130.98

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
108.75

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved